First to Launch, First to Falter? An Investigation Into the Clinical Benefits and HTA Outcomes for First-in-Class Drugs

This investigation provides a comprehensive look at the clinical benefits and HTA outcomes of first-in-class drugs, analysing whether early market entry delivers long-term advantages or challenges.

Presented at ISPOR EU 2024, Barcelona, Spain.

Please click here to download the poster. Don’t forget to subscribe to our newsletter below for the latest company updates, recently published HTA guidance, industry insights, and more!

‍